Prognostic Value of Cardiopulmonary Exercise Test, Pulmonary Function Test, and Questionnaires on Mortality in Patients With Idiopathic Pulmonary Fibrosis: A Prospective Pilot Study

Yuan-Yang Cheng¹,², Shih-Yi Lin,²,³ Shin-Tsu Chang,¹,⁴,⁵,⁶ Chu-Hsing Lin⁷, Pin-Kuei Fu⁷,⁹

¹Department of Physical Medicine and Rehabilitation, Taichung Veterans General Hospital, Taichung, Taiwan
²School of Medicine, National Yang-Ming University, Taipei, Taiwan
³Center for Geriatrics and Gerontology, Taichung Veterans General Hospital, Taichung, Taiwan
⁴Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital, Taipei, Taiwan
⁵School of Medicine, National Defense Medical Center, Taipei, Taiwan
⁶School of Medicine, Chung Shan Medical University, Taichung, Taiwan
⁷Department of Computer Science, Tunghai University, Taichung, Taiwan
⁸Department of Critical Care Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
⁹College of Human Science and Social Innovation, Hungkuang University, Taichung 43302, Taiwan

Corresponding author: Dr. Pin-Kuei Fu

Address requests for reprints to: Dr. Pin-Kuei Fu

Department of Critical Care Medicine, Taichung Veterans General Hospital, Taichung, 40705, Taiwan

1650 Taiwan Boulevard Sect. 4, Taichung, Taiwan 40705
Tel: 886-4-2359-2525 ext 3191; Fax: 886-4-2374-1397
E-mail: yetquen@gmail.com
Abstract

**Background and Objective:** Idiopathic pulmonary fibrosis (IPF) is a lung disease with a high mortality rate. Finding an effective predictor of survival is therefore important for clinicians and patients. Several parameters have been established to predict mortality, but none of these have been validated in the Asian population. In this study, we evaluated the prognostic value of the parameters of cardiopulmonary exercise test (CPET), pulmonary function test (PFT), 6-min walk test (6MWT), and certain questionnaires on mortality in Asian patients with IPF.

**Methods:** This prospective observational study analysed patient data, including age, gender, height, and body weight; scores of Saint George’s Respiratory Questionnaire (SGRQ), Modified Medical Research Council (mMRC) for dyspnoea, and Short Form-36 (SF-36); and parameters of PFT, 6MWT, and CPET.

**Results:** In total, 24 patients diagnosed as having IPF were followed up for 14 months, during which 3 patients died. The nonsurvivors had significantly lower body weight; lower forced vital capacity (FVC); higher ratio of forced expiratory volume in 1 s to forced vital capacity (FEV1/FVC); higher gender, age, and pulmonary physiology (GAP) index; shorter walk distance in 6MWT; lower end-tidal pressure of carbon dioxide (DLCO); higher functional aerobic impairment (FAI) during exercise; and higher mMRC score. FEV1/FVC, FAI, GAP index, and mMRC dyspnoea score demonstrated an area under curve (AUC) of >0.7, and the corresponding cut-off values were 89%, 54%, 7, and 3.

**Conclusions:** The predictive abilities of PFT, CPET, and mMRC scores were validated successfully in the study cohort of Asian patients with IPF.

**Short Title:** Mortality predictors in idiopathic pulmonary fibrosis
Summary at a Glance: Our study examined the survival predictive ability of parameters of cardiopulmonary exercise test, pulmonary function test, and several questionnaires in Asian patients with IPF. The ratio of forced expiratory volume in 1 s to forced vital capacity (FEV1/FVC); functional aerobic impairment; gender, age, and pulmonary physiology (GAP) index; and Modified Medical Research Council (mMRC) dyspnoea scores demonstrated higher prognostic value.

Keywords: Area under the curve, exercise test, pulmonary fibrosis, pulmonary function tests, surveys and questionnaires
1. Introduction

Idiopathic pulmonary fibrosis (IPF) is a type of progressive interstitial lung disease characterised by increased alveolar interstitial inflammation and cell proliferation, culminating in irreversible fibrotic changes.[1] Typically, the diagnosis of IPF is established once chronic hypersensitivity pneumonitis, sarcoidosis, connective tissue diseases, and other specific types of interstitial lung diseases are ruled out.[2] Compared with common chronic pulmonary diseases, the incidence of IPF is lower in East Asia and South America.[3] However, its incidence and mortality rate are increasing steadily worldwide.[4] Despite the disease course being highly variable, the median survival period is approximately 2–3 years from the time of diagnosis.[5] Poor prognosis and the relatively short survival time have made it imperative to identify the appropriate predictors of survival for this patient population.

Tools for monitoring and evaluating the mortality risk of patients with IPF include pulmonary function test (PFT),[6, 7] cardiopulmonary exercise test (CPET),[8-11] and 6-min walk test (6MWT).[12-15] PFT measures the lung volume, capacity, rates of flow, and gas exchange.[16] In IPF, a decrease in forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO) are associated with increased mortality.[17] The survival rate can also be predicted by the 6-month rate of changes in total lung capacity (TLC), FVC, forced expiratory volume in 1 s (FEV1), and DLCO.[6] A lower FEV1/FVC ratio may be significantly associated with a higher survival rate.[7] CPET can predict the mortality rate in patients with idiopathic dilated cardiomyopathy[18] and congestive heart failure,[19, 20] and it can quantify the severity of coronary artery disease.[21] CPET data have been reported to predict mortality in patients with IPF.[8-11] 6MWT is a commonly used surrogate test to predict outcomes in patients with IPF. In 6MWT, the distance walked in 6 min,[22] decrease in the distance walked at 24 weeks,[13] recovery of heart rate after 1 min of
the test,[23] and oxygen desaturation[24] are associated with increased mortality in
patients with IPF. Gender, age, and the two physiologic variables in PFT “FVC” and
“DLCO” have been recently integrated into the gender, age and pulmonary
physiology (GAP) index,[25] which can also precisely predict the survival rate in
patients with IPF.[26]

For monitoring IPF, the commonly used questionnaires that evaluate the overall
health impact and the degree of breathlessness include Saint George’s Respiratory
Questionnaire (SGRQ), Short Form-36 (SF-36), and Modified Medical Research
Council (mMRC) dyspnoea scale. SGRQ is a comprehensive questionnaire to predict
mortality in patients with COPD,[27] but it has also been validated for evaluating
quality of life (QoL)[28, 29] and prognosis[30] in patients with IPF. SF-36 evaluates
patient QoL and can also be applied for patients with IPF,[31, 32] although few
studies have used SF-36 to predict mortality in IPF. The mMRC dyspnoea scale, a
straightforward questionnaire for evaluating the impact of dyspnoea in daily life, has
been demonstrated to predict mortality in patients with COPD[33, 34] or IPF.[35]

Many of the aforementioned tests predict the mortality of patients with IPF, but
only some of them have been validated in Asians.[7, 26, 30, 35] In this study, we
aimed to determine the prognostic value of CPET, PFT, GAP index, SGRQ score,
mMRC score, and SF-36 score for mortality in patients with IPF. We hypothesised
that the parameters of CPET (e.g., maximal oxygen consumption) and PFT (e.g.,
FVC) can more effectively predict the survival rate because of their objective design.

2. Materials and Methods

2.1. Study design

This prospective observational cohort study was conducted in a tertiary medical
centre in central Taiwan. Patients diagnosed as having ILD and who agreed to provide
informed consent were enrolled from Dec 2018 to April 2020. The study protocol was reviewed and approved by the Institutional Review Board of Taichung Veterans General Hospital (IRB number, CE18325B; date of approval, Dec 18, 2018).

2.2 Study population and setting

In this study, a subgroup analysis of patients with a definite diagnosis of IPF according to the criteria of the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association was conducted.[36] The parameters included patient demographic data such as age, sex, height, body weight, and occupation. The index day was defined as the day on which the patient signed the inform consent form. The participants completed SGRQ, SF-36, and mMRC dyspnoea questionnaires on the index day. Within 1 week of enrolment, the participants were administered PFT, 6MWT and CPET. The patients were followed up for 14 months to trace the major outcomes, which included acute exacerbation, hospital admission, and mortality.

2.3 Pulmonary function test

In this study, PFT included two components. First, spirometry was conducted, which involves a period of quiet breathing, followed by expiration into the sensor as quickly and as long as possible after taking the deepest inspiration. FVC and FEV1 data were obtained from the results of the spirometry. Second, the difference in the partial pressure between the inspired and expired carbon monoxide was measured. After a deep inspiration, the participants had to hold their breath for 8–12 s. The DLCO value was obtained by measuring the subsequent air expiration. Both measurements were performed in accordance with the recommendations of the American Thoracic Society.[37]

2.4 Cardiopulmonary exercise test

We performed CPET by using an electromagnetically braked cycle ergometer.
All test procedures were performed in accordance with the guidelines of the American Heart Association and comprised 3-min rest and 3-min of unloaded pedalling, pedalling with the brake gradually applied in a ramp manner up to the maximal level tolerated by the patient, and unloaded pedalling for 3 min.[38] CPET provided the following data: oxygen consumption in relation to body weight (VO2/kg), functional aerobic impairment (FAI; ratio of the difference between the observed and the predicted peak oxygen consumption to the predicted peak oxygen consumption), percentage peak oxygen consumption in relation to the heart rate (O2 pulse), end-tidal partial pressure of carbon dioxide (PETCO2) at maximal exercise, minute ventilation to carbon dioxide output (VE/VCO2) slope, heart rate recovery at 1 min after peak exercise (HR recovery), O2 desaturation, ratio of dead space to tidal volume at rest (maximal Vd/Vt), and maximal exercise (minimal Vd/Vt) and change in Vd/Vt during the test.[39]

2.5 Six-Minute Walk Test

6MWT was performed in accordance with the guidelines of the American Thoracic Society. The patients were instructed to walk as far as possible for 6 min in a corridor between the two orange traffic cones placed 30-m apart.[40] Data on oxygen saturation and the distance walked in 6 min were obtained.

2.6 Statistical analysis

All the data were analysed using IBM SPSS Statistics 23.0 (Armonk, New York, USA) software. The Shapiro–Wilk test was used to examine variables with a normal distribution. For non-normally distributed data, the Mann–Whitney U and Fisher exact tests were used to determine the presence of any significant difference between survivors and nonsurvivors. The chi-square test was used to analyse discrete variables. Cox proportional regression analysis was performed for all the parameters measured. Subsequently, receiver operating characteristic (ROC) curve analysis was
performed for the parameters that were significantly different between the survivors and nonsurvivors. The parameters with areas under curve (AUCs) of $>0.7$ were identified, and the cut-off points were decided to maximise the sum of sensitivity and specificity values of the respective ROC curves. Furthermore, the De Long test was used to determine the differences between the AUCs of each two parameters. A $p$ value of $<0.05$ was considered significant.

3. Results

In total, 24 patients with IPF were enrolled into this study, with a follow-up duration of 14 months. Three patients died during the follow-up, with a survival duration of 44, 201, and 319 days, respectively. Patient data, including age; gender; height; body weight; mMRC, SGRQ, and SF-36 scores; and 6MWT, PFT and CPET data were collected and compared between the survivors and nonsurvivors (Table 1). We found no significant differences in age or gender between the groups, but the nonsurvivors had significantly lower body weight and body mass index (BMI; Table 1). In intergroup comparison, lower FVC and FEV1, higher FEV1/FVC, and higher GAP values were found to be significantly associated with mortality (Table 1). The survivors demonstrated significantly longer walk distance in 6MWT, higher PETCO2 and lower FAI during maximal exercise (Table 1) and significantly lower mMRC scores.

The predictors of mortality were examined through univariable Cox regression analysis, and the data are presented in Table 2. Only the distance walked in 6MWT and the GAP index demonstrated significantly higher hazards ratio (HRs) for survival (6MWT distance: HR: 1.00, 95% confidence interval [CI], 0.99–1.01, $p = 0.949$; GAP index: 2.52, 0.64–9.89, $p = 0.185$). Further analysis of the data using the multivariable Cox regression model failed to identify any further parameters with a significant $p$
value. ROC curve analysis was performed to further identify the predictors by excluding the effect of time to mortality. As shown in Table 3, the percentage of FEV1/FVC, FAI, GAP index, and mMRC score had an AUC of >0.7, and the corresponding cut-off values were 89%, 54%, 7, and 3. The ROC curve analysis for these four parameters is presented in Figure 1. The results of the De Long test, presented in Table 4, did not demonstrate significant differences between the AUC of each two of the four parameters, including the percentage of FEV1/FVC, FAI, GAP index, and mMRC score.

4. Discussion

In this preliminary study, we established the predictive value of PFT, CPET, and mMRC dyspnoea score for mortality in an Asian cohort of patients with IPF. Although statistical significance could not be achieved in the multivariable Cox regression analysis, the four important parameters FEV1/FVC in PFT, FAI in CPET, GAP index, and mMRC dyspnoea score with a significantly large AUC in the ROC curve analysis were identified. These parameters can provide a reference to enable healthcare workers to more effectively manage Asian patients with IPF. To the best of our knowledge, this is the first study to confirm the mortality predictive role of CPET for Asian patients with IPF.

In contrast to past studies,[8, 10] which have established that the absolute value of VO2/kg can serve as a survival predictor, our study highlighted the importance of the difference between the predicted and observed oxygen consumption. Typically, the maximal oxygen consumption in a healthy person can be predicted on the basis of age, sex, body height, and body weight,[41] and older women demonstrate lower oxygen consumption and older male patients with IPF demonstrate higher mortality.[25] Therefore, using the absolute value of VO2/kg instead of FAI in female
patients with IPF could have the potential hazard of overestimating mortality. For example, an 80-year-old female patient in our survivor cohort demonstrated a considerably low VO2/kg value of 13.9 mL/min/kg during CPET. However, her FAI was only 15.17%, because her oxygen consumption during exercise was not significantly lower than the predicted value. Hence, using FAI to reflect the true difference in oxygen consumption between the observed and predicted value could more effectively predict mortality theoretically, and our results support this inference. We suggest the FAI can be used to predict mortality both in normal and overweight people[42] and in patients with IPF.[11] However, these findings from the pilot study require further investigation.

IPF is a restrictive lung disease, reflected by lowered PFT FVC, which has been shown to predict mortality in patients with IPF.[6, 17] By contrast, in our study, the higher percentage of FEV1/FVC was a more favourable mortality predictor, which could be attributed to faster progression in the decrement of FVC than FEV1 in the IPF disease course. A higher percentage of FEV1/FVC may signify an advanced stage of IPF and, therefore, higher mortality. Our results are in line with those of a few earlier studies.[7, 43, 44] Nishiyama et al. suggested FEV1/FVC as a significant predictor of survival in the Asian population.[7] Furthermore, their data revealed FEV1/FVC as an independent predictor in the multivariate analysis,[7] implying that the predictive ability of higher FEV1/FVC in mortality is not completely caused by lowered FVC. Our data also suggested the same phenomenon, although the reason for this finding remains unclear.

Since 2012, the GAP index, which is derived from the patient’s gender, age, FVC, and DLCO, has been used for survival prediction.[25] In addition, the index has been successfully validated in the Asian population.[45] In our study, although the AUCs of FVC and DLCO were not large enough to predict mortality, the GAP index,
with an AUC as high as 0.96, is a potential predictor of survival. In contrast to the original version of GAP staging, which has two cut-off values (i.e., ≤3 and ≥6), our result demonstrated only a single cut-off value of ≥7. This could be because of the predominance of men (79.17%) and older patients (66.42 ± 10.88 years) in our study cohort, which could have elevated the cut-off value, or the small sample size.

In our study, the mMRC, a simple questionnaire, demonstrated the highest AUC of 0.98, which is in line with the study by Nishiyama et al., who validated the predictive ability of mMRC in patients with IPF.[35] In our study, a cut-off value of ≥3 had predictive mortality for patients with IPF, which is higher than the cut-off value of ≥2 for patients with COPD in an earlier study.[34]

Our study has some limitations. First, the follow-up period was shorter; thus, only a limited number of mortality cases were assessed. If any of the data of the nonsurvivors were statistical outliers, the results of our study could be significantly affected. Second, the sample size was small. This was because of the relatively low prevalence of IPF in Taiwan (2.0–4.9 cases/100,000 persons).[46] If more patients were to be included in our study, the results of the multivariate Cox regression and Kaplan–Meier curve analysis would have been more convincing. However, our study was a prospective single-centred observational study of patients with newly diagnosed IPF. These preliminary results still hold value, especially for healthcare workers managing Asian patients with IPF.

5. Conclusions

For the first time, we demonstrated the potential survival prediction value of FAI during CPET in Asian patients with IPF. Moreover, the percentage of FEV1/FVC, GAP index, and mMRC dyspnoea score were favourable predictors of mortality. In areas where facilities for PFT or CPET are unavailable, healthcare workers can
include the simple questionnaire of mMRC for dyspnoea to predict survival.

However, further studies with larger study cohorts and longer follow-up durations are warranted to support our findings.

**Declarations**

**Ethics approval and consent to participate:** The study protocol was reviewed and approved by the Institutional Review Board of Taichung Veterans General Hospital (IRB number, CE18325B; date of approval, Dec 18, 2018). Patients diagnosed as having ILD and who agreed to provide informed consent were enrolled from Dec 2018 to April 2020.

**Consent for publication:** Not applicable

**Availability of data and materials:** All data generated or analysed during this study are included in this published article

**Funding:** No funding was received in the current study.

**Author Contributions:** Y.Y.C. and P.K.F. contributed to the research, data review and collection, and statistical analyses. Y.Y.C., S.Y.L., and S.T.C. were responsible for data collection and statistical analyses. Y.Y.C., S.Y.L., S.T.C., C.H.L., and P.K.F. were responsible for data coding and result interpretation. Y.Y.C. and P.K.F. were responsible for the study design, result interpretation, and manuscript preparation. All of the authors discussed the results and contributed to the preparation of the final manuscript. All authors read and approved the final manuscript.

**Acknowledgments:** The authors acknowledge the Biostatistics Task Force of Taichung Veterans General Hospital, Taichung, Taiwan, ROC, for statistical assistance.

**Conflicts of Interest:** The authors have no conflicts of interest to declare.
Figure Legends

Figure 1. Curve of ROC analysis for the four parameters include FEV1/FVC, GAP score, mMRC score, and FAI (%).
Table 1. Parameters of patients with IPF stratified by survival status

| Parameter                               | Overall (n = 24) | Survivors (n = 21; 87.5%) | Non-survivors (n = 3; 12.5%) | p value |
|-----------------------------------------|------------------|---------------------------|-----------------------------|---------|
| Age (years)                             | 66.42 ±10.88     | 66.05 ±11.60              | 69.00 ±2.00                 | 0.988   |
| Sex, n (%)                              |                  |                           |                             | 1.000   |
| Female                                  | 5 (20.83)        | 5 (23.81)                 | 0 (0)                      |         |
| Male                                    | 19 (79.17)       | 16 (76.19)                | 3 (100)                    |         |
| Height (cm)                             | 164.70 ±9.37     | 164.73 ±9.85              | 164.47 ±6.24               | 0.870   |
| Body weight (kg)                        | 64.62 ±14.25     | 66.76 ±13.85              | 49.60 ±5.74                | 0.030*  |
| Body mass index (kg/m²)                 | 23.67 ±4.12      | 24.44 ±3.77               | 18.34 ±1.87                | 0.016*  |
| VO2/kg (ml/kg/min)                      | 14.68 ±3.65      | 14.99 ±3.78               | 12.47 ±1.46                | 0.278   |
| FAI (%)                                 | 43.77 ±16.69     | 41.42 ±16.48              | 60.23 ±4.48                | 0.041*  |
| O2 pulse (%)                            | 72.04 ±20.96     | 74.62 ±21.03              | 54.00 ±8.66                | 0.061   |
| PETCO2 (kPa)                            | 3.69 ±0.67       | 3.80 ±0.64                | 2.94 ±0.29                 | 0.015*  |
| VE/VCO2 slope                           | 38.52 ±8.30      | 37.36 ±7.69               | 46.67 ±9.29                | 0.145   |
| HR recovery (beat)                      | 10.04 ±7.78      | 11.10 ±7.73               | 2.67 ±2.52                 | 0.051   |
| O2 desaturation (%)                     | 6.08 ±4.85       | 5.76 ±4.44                | 8.33 ±8.08                 | 0.625   |
| Maximal Vd/Vt                           | 32.38 ±11.02     | 31.52 ±10.67              | 38.33 ±14.05               | 0.397   |
| Minimal Vd/Vt                           | 26.92 ±12.24     | 25.95 ±11.56              | 33.67 ±17.50               | 0.445   |
| Change of Vd/Vt during CPET             | 5.46 ±3.09       | 5.57 ±3.08                | 4.67 ±3.79                 | 0.378   |
| FVC (liter)                             | 2.17 ±0.76       | 2.31 ±0.70                | 1.20 ±0.18                 | 0.023*  |
| FVC (% predicted)                       | 70.29 ±23.43     | 74.05 ±22.48              | 44.00 ±8.72                | 0.030*  |
| Parameter                          | Value 1  | ±        | Value 2  | ±        | Value 3  | ±        | Value 4  | ±        | Value 5  | ±        | p-value |
|-----------------------------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|---------|
| FEV1 (liter)                      | 1.80     | ±0.53    | 1.90     | ±0.49    | 1.10     | ±0.12    | 0.022*   |          |          |          |         |
| FEV1 (% predicted)                | 73.63    | ±22.40   | 76.81    | ±22.05   | 51.33    | ±7.57    | 0.051    |          |          |          |         |
| FEV1/FVC (%)                      | 85.21    | ±9.19    | 84.10    | ±9.16    | 93.00    | ±5.29    | 0.035*   |          |          |          |         |
| DLCO (ml/min/mmHg)                | 11.64    | ±4.14    | 11.99    | ±3.93    | 4.93     |          | 0.100    |          |          |          |         |
| DLCO (% predicted)                | 63.90    | ±23.78   | 65.63    | ±23.09   | 31.00    |          | 0.100    |          |          |          |         |
| GAP index                         | 3.88     | ±2.03    | 3.38     | ±1.63    | 7.33     | ±0.58    | 0.004**  |          |          |          |         |
| 6MWT data                         |          |          |          |          |          |          |          |          |          |          |         |
| Resting oxygen saturation (%)     | 95.17    | ±2.01    | 95.38    | ±1.96    | 93.67    | ±2.08    | 0.186    |          |          |          |         |
| Exercise oxygen saturation (%)    | 86.96    | ±5.82    | 87.86    | ±5.33    | 80.67    | ±6.11    | 0.050    |          |          |          |         |
| Oxygen desaturation in 6MWT (%)   | 8.21     | ±5.34    | 7.52     | ±4.71    | 13.00    | ±8.19    | 0.208    |          |          |          |         |
| Distance walked (meters)          | 375.25   | ±138.52  | 403.10   | ±110.07  | 180.33   | ±185.41  | 0.031*   |          |          |          |         |
| mMRC score                        | 1.33     | ±1.24    | 1.00     | ±0.89    | 3.67     | ±0.58    | 0.001**  |          |          |          |         |
| SGRQ score                        |          |          |          |          |          |          |          |          |          |          |         |
| Symptoms score                    | 40.61    | ±21.12   | 38.66    | ±21.93   | 52.93    | ±9.62    | 0.129    |          |          |          |         |
| Activity score                    | 57.15    | ±24.67   | 54.97    | ±24.27   | 67.29    | ±29.24   | 0.451    |          |          |          |         |
| Impacts score                     | 37.27    | ±27.49   | 33.90    | ±25.70   | 55.22    | ±35.66   | 0.138    |          |          |          |         |
| Total score                       | 46.82    | ±23.62   | 44.32    | ±22.87   | 58.50    | ±28.55   | 0.362    |          |          |          |         |
| SF-36 score                       |          |          |          |          |          |          |          |          |          |          |         |
| Physical domain score             | 53.53    | ±19.91   | 54.82    | ±20.38   | 40.00    | ±3.54    | 0.431    |          |          |          |         |
| Mental domain score               | 55.36    | ±22.91   | 56.04    | ±23.53   | 48.25    | ±19.09   | 0.565    |          |          |          |         |
| Total score                       | 54.45    | ±20.50   | 55.43    | ±21.08   | 44.13    | ±11.31   | 0.514    |          |          |          |         |

CPET, cardiopulmonary exercise test; DLCO, diffusing capacity of the lungs for carbon monoxide; FAI, Functional aerobic impairment; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; GAP index, gender, age, and the pulmonary physiology index; HR, heart rate.
rate; IPF, idiopathic pulmonary fibrosis; mMRC, Modified Medical Research Council; PETCO₂, end-tidal partial pressure of carbon dioxide; PFT, pulmonary function test; SF-36, Short Form-36; SGRQ, Saint George’s Respiratory Questionnaire; Vd/Vt, ratio of dead space to tidal volume at rest; VE/VCO₂, minute ventilation to carbon dioxide output; VO₂/kg, oxygen consumption in relation to body weight; 6MWT, 6-min walk test.

*p < 0.05, **p < 0.001.
|                       | Univariate model |                  |                  |                  |
|-----------------------|------------------|------------------|------------------|------------------|
|                       | HR               | (95% CI)         | p value          |
| Age                   | 1.03             | (0.88–1.20)      | 0.744            |
| Gender (male vs. female) | 27.15          | (0.00–16694714.86) | 0.627            |
| Height                | 1.00             | (0.87–1.15)      | 0.994            |
| Body weight           | 0.92             | (0.84–1.01)      | 0.091            |
| Body mass index       | 0.72             | (0.51–1.02)      | 0.067            |
| CPET data             |                  |                  |                  |
| VO2/kg                | 0.83             | (0.56–1.23)      | 0.354            |
| FAI (%)               | 1.12             | (0.97–1.28)      | 0.114            |
| O2 pulse              | 0.94             | (0.86–1.02)      | 0.134            |
| PETCO2                | 0.03             | (0.00–4.33)      | 0.164            |
| VE/VCO2 slope         | 1.11             | (0.97–1.27)      | 0.127            |
| Heart rate recovery   | 0.74             | (0.49–1.13)      | 0.170            |
| O2 desaturation       | 1.07             | (0.87–1.33)      | 0.519            |
| Maximal Vd/Vt         | 1.07             | (0.96–1.19)      | 0.201            |
| Minimal Vd/Vt         | 1.08             | (0.97–1.20)      | 0.167            |
| Change of Vd/Vt during CPET | 0.83 | (0.51–1.35) | 0.450 |
| PFT data              |                  |                  |                  |
| FVC                   | 0.12             | (0.01–1.24)      | 0.076            |
| FVC (% predicted)     | 0.94             | (0.87–1.01)      | 0.104            |
| FEV1                  | 0.06             | (0.00–1.35)      | 0.077            |
| FEV1 (% predicted)    | 0.94             | (0.86–1.02)      | 0.132            |
| FEV1/FVC (%)          | 1.14             | (0.95–1.37)      | 0.167            |
| DLCO                  | 0.25             | (0.01–4.61)      | 0.349            |
| DLCO (% predicted)    | 0.78             | (0.38–1.61)      | 0.499            |
| GAP index             | 2.60             | (1.01–6.70)      | 0.047*           |
| 6MWT data             |                  |                  |                  |
| Resting oxygen saturation | 0.72 | (0.41–1.27) | 0.259 |
| Exercise oxygen saturation | 0.85 | (0.71–1.03) | 0.101 |
| Oxygen desaturation in 6MWT | 1.13 | (0.95–1.35) | 0.170 |
| Distance walked       | 0.99             | (0.98–1.00)      | 0.034*           |
| mMRC score            | 38.54            | (0.13–11427.75)  | 0.209            |
| SGRQ score            |                  |                  |                  |
| Symptoms score        | 1.02             | (0.98–1.07)      | 0.355            |
| Activity score        | 1.02             | (0.97–1.08)      | 0.451            |
|                        |       |           |       |
|------------------------|-------|-----------|-------|
| Impacts score          | 1.03  | (0.98–1.09) | 0.267 |
| Total score            | 1.03  | (0.97–1.09) | 0.361 |
| SF-36 score            |       |           |       |
| Physical domain score  | 0.96  | (0.86–1.07) | 0.456 |
| Mental domain score    | 0.99  | (0.93–1.06) | 0.873 |
| Total score            | 0.98  | (0.90–1.07) | 0.653 |

CI, confidence interval; CPET, cardiopulmonary exercise test; DLCO, diffusing capacity of the lungs for carbon monoxide; FAI, functional aerobic impairment; FVC; forced vital capacity; FEV1; forced expiratory volume in 1 s; GAP index, gender, age, and the pulmonary physiology index; HR, hazard ratio; IPF, idiopathic pulmonary fibrosis; mMRC, Modified Medical Research Council; PETCO2, end-tidal partial pressure of carbon dioxide; PFT, pulmonary function test; SF-36, Short Form-36; SGRQ, Saint George’s Respiratory Questionnaire; Vd/Vt, ratio of dead space to tidal volume at rest; VE/VCO2, minute ventilation to carbon dioxide output; VO2/kg, oxygen consumption in relation to body weight; 6MWT, 6-min walk test. *p < 0.05.
**Table 3.** ROC curve analysis of the parameters with significant differences between the survivors and nonsurvivors

| Parameter       | AUC    | p value  | Cut-off point | Sensitivity | Specificity | Accuracy | PPV | NPV |
|-----------------|--------|----------|---------------|-------------|-------------|----------|-----|-----|
| mMRC            | 0.98   | 0.008**  | ≥3            | 100         | 90.48       | 91.67    | 60  | 100 |
| GAP index       | 0.96   | 0.011*   | ≥7            | 100         | 95.24       | 95.83    | 75  | 100 |
| FEV1/FVC (%)    | 0.87   | 0.040*   | ≥89           | 100         | 76.19       | 79.17    | 37.5| 100 |
| FAI (%)         | 0.87   | 0.040*   | ≥54           | 100         | 80.95       | 83.33    | 42.86| 100 |

AUC, area under the curve; FAI, functional aerobic impairment; FVC, forced vital capacity; FEV1; forced expiratory volume in 1 s; GAP index, gender, age and the pulmonary physiology index; mMRC, Modified Medical Research Council; NPV, negative predictive value; PPV, positive predictive value; ROC, receiver operating characteristic.

*p < 0.05, **p < 0.01

**Table 4.** Differences in the AUC between each of the two parameters of FEV1/FVC, GAP index, FAI, and mMRC on the De Long test

| Parameter       | p       |  |
|-----------------|---------|---|
| FEV1/FVC (%)    | GAP index | 0.220 |
|                 | mMRC     | 0.135 |
|                 | FAI (%)  | 1.000 |
| GAP index       | mMRC     | 0.507 |
|                 | FAI (%)  | 0.333 |
| mMRC            | FAI (%)  | 0.170 |

Functional aerobic impairment, FVC; forced vital capacity; FEV1; forced expiratory volume in 1 s; GAP index, gender, age, and the pulmonary physiology index; mMRC, Modified Medical Research Council.
**Figure 1.** ROC curve analysis for the four parameters of FEV1/FVC, GAP score, mMRC score, and FAI (%)

Functional aerobic impairment, FVC; forced vital capacity: FEV1; forced expiratory volume in 1 s; GAP index, gender, age, and the pulmonary physiology index; mMRC, Modified Medical Research Council; ROC, receiver operating characteristic.
References:

1. Lederer DJ, Martinez FJ: *Idiopathic Pulmonary Fibrosis*. *N Engl J Med* 2018, 378:1811-1823.
2. Richeldi L, Collard HR, Jones MG: *Idiopathic pulmonary fibrosis*. *Lancet* 2017, 389:1941-1952.
3. Hutchinson J, Fogarty A, Hubbard R, McKeever T: *Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review*. *Eur Respir J* 2015, 46:795-806.
4. Hutchinson JP, McKeever TM, Fogarty AW, Navaratnam V, Hubbard RB: *Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century*. *Ann Am Thorac Soc* 2014, 11:1176-1185.
5. Kim HJ, Perlman D, Tomic R: *Natural history of idiopathic pulmonary fibrosis*. *Respir Med* 2015, 109:661-670.
6. Collard HR, King TE, Jr., Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK: *Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis*. *Am J Respir Crit Care Med* 2003, 168:538-542.
7. Nishiymama O, Yamazaki R, Sano A, Yamagata T, Sano H, Iwanaga T, Higashimoto Y, Kume H, Tohda Y: *Prognostic value of forced expiratory volume in 1 second/forced vital capacity in idiopathic pulmonary fibrosis*. *Chron Respir Dis* 2016, 13:40-47.
8. Triantafillidou C, Manali E, Lyberopoulos P, Kolilekas L, Kagouridis K, Gyftopoulos S, Vougas K, Kotanidou A, Alchanatis M, Karakatsani A, Papiris SA: *The Role of Cardiopulmonary Exercise Test in IPF Prognosis*. *Pulm Med* 2013, 2013:514817.
9. Vainshelboim B, Oliveira J, Fox BD, Kramer MR: *The Prognostic Role of Ventilatory Inefficiency and Exercise Capacity in Idiopathic Pulmonary Fibrosis*. *Respir Care* 2016, 61:1100-1109.
10. Fell CD, Liu LX, Motika C, Kazerooni EA, Gross BH, Travis WD, Colby TV, Murray S, Toews GB, Martinez FJ, Flaherty KR: *The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis*. *Am J Respir Crit Care Med* 2009, 179:402-407.
11. Glaser S, Obst A, Koch B, Henkel B, Griefer A, Felix SB, Halank M, Bruch L, Bollmann T, Warnke C, et al: *Pulmonary hypertension in patients with idiopathic pulmonary fibrosis - the predictive value of exercise capacity and gas exchange efficiency*. *PLoS One* 2013, 8:e65643.
12. Lancaster LH: *Utility of the six-minute walk test in patients with idiopathic pulmonary fibrosis*. *Multidiscip Respir Med* 2018, 13:45.
13. du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, Sahn SA, Valleyre D, Weycker D, King TE: **6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.** *European Respiratory Journal* 2014, **43:**1421-1429.
14. Swigris JJ, Olson AL, Shlobin OA, Ahmad S, Brown KK, Nathan SD: **Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis.** *Respirology* 2011, **16:**439-445.
15. Brown AW, Nathan SD: **The Value and Application of the 6-Minute-Walk Test in Idiopathic Pulmonary Fibrosis.** *Ann Am Thorac Soc* 2018, **15:**3-10.
16. Ranu H, Wilde M, Madden B: **Pulmonary function tests.** *The Ulster medical journal* 2011, **80:**84-90.
17. Glaspole I, Goh N, Hopio P, Moodley Y, Reynolds P, Walters H, Zappala C, Allan H, Chapman S, Cooper W, et al: **Baseline Pulmonary Function Test Predicts Survival: Analysis from the Australian IPF Registry.** In *C39 IPF: MORE ON DIAGNOSIS AND THERAPY. A5004-A5004*
18. Sinagra G, Iorio A, Merlo M, Cannata A, Stolfo D, Zambon E, Di Nora C, Paolillo S, Barbati G, Berton E, et al: **Prognostic value of cardiopulmonary exercise testing in Idiopathic Dilated Cardiomyopathy.** *Int J Cardiol* 2016, **223:**596-603.
19. Poggio R, Arazi HC, Giorgi M, Miriuaka SG: **Prediction of severe cardiovascular events by VE/VCO2 slope versus peak VO2 in systolic heart failure: a meta-analysis of the published literature.** *Am Heart J* 2010, **160:**1004-1014.
20. Czubaszewski L, Straburzynska-Lupa A, Migaj J, Straburzynska-Migaj E: **Comparison of prognostic values of cardiopulmonary and heart rate parameters in exercise testing in men with heart failure.** *Cardiol J* 2018, **25:**701-708.
21. Popovic D, Guazzi M, Jakovljevic DG, Lasica R, Banovic M, Ostojic M, Arena R: **Quantification of coronary artery disease using different modalities of cardiopulmonary exercise testing.** *Int J Cardiol* 2019, **285:**11-13.
22. Mancuzo EV, Soares MR, Pereira CAC: **Six-minute walk distance and survival time in patients with idiopathic pulmonary fibrosis in Brazil.** *J Bras Pneumol* 2018, **44:**267-272.
23. Swigris JJ, Swick J, Wamboldt FS, Sprungner D, du Bois R, Fischer A, Cosgrove GP, Frankel SK, Fernandez-Perez ER, Kervitsky D, Brown KK: **Heart rate recovery after 6-min walk test predicts survival in patients with idiopathic pulmonary fibrosis.** *Chest* 2009, **136:**841-848.
24. Lettieri CJ, Nathan SD, Browning RF, Barnett SD, Ahmad S, Shorr AF: **The distance-saturation product predicts mortality in idiopathic pulmonary...**
fibrosis. *Respir Med* 2006, 100:1734-1741.

25. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Bucciol M, Elicker BM, Jones KD, et al: **A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis.** *Annals of Internal Medicine* 2012, 156:684-691.

26. Lee SH, Kim SY, Kim DS, Kim YW, Chung MP, Uh ST, Park CS, Jeong SH, Park YB, Lee HL, et al: **Predicting survival of patients with idiopathic pulmonary fibrosis using GAP score: a nationwide cohort study.** *Respir Res* 2016, 17:131.

27. Havlucu Y, Yorgancıoglu A, Coskun AS, Celik P: **Does one year change in quality of life predict the mortality in patients with chronic obstructive pulmonary disease?**—**Prospective cohort study.** *Journal of Thoracic Disease* 2019, 11:3626-3632.

28. Capparelli I, Fernandez M, Saadia Otero M, Steinberg J, Brassesco M, Campobasso A, Palacios S, Caro F, Alberti ML, Rabinovich RA, Paulin F: **Translation to Spanish and Validation of the Specific Saint George’s Questionnaire for Idiopathic Pulmonary Fibrosis.** *Arch Bronconeumol* 2018, 54:68-73.

29. Xu Z, Li H, Wen F, Bai C, Chen P, Fan F, Hu N, Stowasser S, Kang J: **Subgroup Analysis for Chinese Patients Included in the INPULSIS((R)) Trials on Nintedanib in Idiopathic Pulmonary Fibrosis.** *Adv Ther* 2019, 36:621-631.

30. Furukawa T, Taniguchi H, Ando M, Kondoh Y, Kataoka K, Nishiyama O, Johkoh T, Fukuoka J, Sakamoto K, Hasegawa Y: **The St. George’s Respiratory Questionnaire as a prognostic factor in IPF.** *Respiratory Research* 2017, 18:18.

31. Verma G, Marras T, Chowdhury N, Singer L: **Health-Related Quality of Life and 6 Min Walk Distance in Patients with Idiopathic Pulmonary Fibrosis.** *Canadian Respiratory Journal* 2011, 18:109635.

32. Zimmermann CS, Carvalho CRF, Silveira KR, Yamaguti WPS, Moderno EV, Salge JM, Kairalla RA, Carvalho CRR: **Comparison of two questionnaires which measure the health-related quality of life of idiopathic pulmonary fibrosis patients.** *Brazilian Journal of Medical and Biological Research* 2007, 40:179-187.

33. Henoch I, Strang S, Löfdahl C-G, Ekberg-Jansson A: **Health-related quality of life in a nationwide cohort of patients with COPD related to other characteristics.** *European clinical respiratory journal* 2016, 3:31459-31459.

34. Casanova C, Marin JM, Martinez-Gonzalez C, de Lucas-Ramos P, Mir-Viladrich I, Cosio B, Peces-Barba G, Solanes-Garcia I, Aguero R, Feu-Collado N, et al: **Differential Effect of Modified Medical Research Council Dyspnea, COPD**
Assessment Test, and Clinical COPD Questionnaire for Symptoms Evaluation Within the New GOLD Staging and Mortality in COPD. *Chest* 2015, **148**:159-168.

35. Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Kato K, Kataoka K, Ogawa T, Watanabe F, Arizono S: A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. *European Respiratory Journal* 2010, **36**:1067-1072.

36. Raghu G: Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. 2018, **198**:e44-e68.

37. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al: Standardisation of spirometry. *Eur Respir J* 2005, **26**:319-338.

38. Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, Forman D, Franklin B, Guazzi M, Gulati M, et al: Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. *Circulation* 2010, **122**:191-225.

39. Bruce RA, Kusumi F, Hosmer D: Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease. *American Heart Journal* 1973, **85**:546-562.

40. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med* 2002, **166**:111-117.

41. Takken T, Mylius CF, Paap D: Reference values for cardiopulmonary exercise testing in healthy subjects - an updated systematic review. 2019, **17**:413-426.

42. Abudiab M, Aijaz B, Konecny T, Kopecky SL, Squires RW, Thomas RJ, Allison TG: Use of functional aerobic capacity based on stress testing to predict outcomes in normal, overweight, and obese patients. *Mayo Clin Proc* 2013, **88**:1427-1434.

43. Schwartz DA, Helmers RA, Galvin JR, Van Fossen DS, Frees KL, Dayton CS, Burmeister LF, Hunninghake GW: Determinants of survival in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 1994, **149**:450-454.

44. King TE, Jr., Tooze JA, Schwarz MI, Brown KR, Cherniack RM: Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. *Am J Respir Crit Care Med* 2001, **164**:1171-1181.

45. Kim ES, Choi SM, Lee J, Park YS, Lee CH, Yim JJ, Yoo CG, Kim YW, Han SK, Lee SM: Validation of the GAP score in Korean patients with idiopathic pulmonary fibrosis. *Chest* 2015, **147**:430-437.
Lin HI, et al: Idiopathic pulmonary fibrosis in Taiwan - a population-based study. *Respir Med* 2012, *106*:1566-1574.